| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 131.12 | 0.02 (+0.01%) | 42.83 - 145.04 | 789.2 thousand |
Market data as of 4:00PM 05/16/12. Quotes are delayed by at least 15 min.
| Open | 131.70 |
|---|---|
| Previous Close | 131.10 |
| Day's Range | 129.97 - 132.99 |
| Market Cap | 12.2B |
| Avg Volume (10 Day) | 759.2K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -1.84 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Fail |
| Increased shareholder value? | Fail |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Neutral |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Fail |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Regeneron Announces Presentation at the Bank of America Merrill Lynch 2012 Healthcare Conference
PR Newswire - Thursday 05/10/2012 9:30 AM ET
Regeneron Announces Participation in J. P. Morgan Biotech: CEO/CFO Conference Call Series
PR Newswire - Wednesday 05/09/2012 9:30 AM ET
Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
PR Newswire - Tuesday 05/08/2012 5:04 PM ET
Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
PR Newswire - Tuesday 05/08/2012 2:00 AM ET
Regeneron Reports First Quarter 2012 Financial and Operating Results
PR Newswire - Thursday 04/26/2012 6:30 AM ET
| REGN | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 20.88% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.87 | |
| LT Debt/Equity | 0.87 | |
| Earnings Yield | -- | |
| Price/Sales | 22.06 |
| Company | Last | Change |
|---|---|---|
| Vertex Pharmaceuticals Inc | 62.61 | -1.21% |
| Alexion Pharmaceuticals Inc | 86.99 | +0.30% |
| Shire PLC | 94.13 | -1.44% |
| Illumina Inc | 44.63 | +0.13% |
| BioMarin Pharmaceutical Inc | 38.46 | -0.83% |
Data is delayed by at least 15 min.